VCYT - Company ID 0001384101
VERACYTE, INC. trades as VCYT and has a market capitalization of $4.73 B, making it the #1462 largest US-listed company by market value. In its fiscal 2025 annual report the company posted revenue of $517.14M, up 16.0% from the prior year and net income of $66.40M. This page tracks VERACYTE, INC. through 1,124 SEC filings, with financial statements and metrics updated as new reports are filed.
Research snapshot
Updated
2026-07-09
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
Next research step
Over the last 9 fiscal years VERACYTE, INC.'s revenue grew from $65.08M to $517.14M, a compound annual growth rate of 25.9%. Net profit margin expanded from -25.0% to 12.8% over the same period - every figure below comes from the company's audited annual filings.
Dig into the full income statement, balance sheet, and cash flow statement with annual and quarterly views.
| Filing | Type | Filed |
|---|---|---|
| Insider trade | 4 | 2026-05-22 |
| Insider sale notice | 144 | 2026-05-20 |
| SCHEDULE 13G/A | - | 2026-05-13 |
| SCHEDULE 13G | - | 2026-05-12 |
| Insider trade | 4 | 2026-05-08 |
| Insider sale notice | 144 | 2026-05-06 |
| Quarterly report | 10-Q | 2026-05-06 |
| SCHEDULE 13G/A | - | 2026-05-06 |
Veracyte to Host Investor Call on June 1, 2026 to Discuss ASCO Findings | Veracyte, Inc.
OPTIMA Trial Results to Be Presented at ASCO Provide New Evidence Supporting Prosigna-Guided Chemotherapy Decisions in Breast Cancer | Veracyte, Inc.
Veracyte to Participate in Upcoming Investor Conferences | Veracyte, Inc.
Veracyte Secures Medicare Coverage for TrueMRD Monitoring Test in Muscle-Invasive Bladder Cancer | Veracyte, Inc.
Veracyte Announces First Quarter 2026 Financial Results | Veracyte, Inc.
The largest companies sharing VERACYTE, INC.'s SEC industry classification (services-medical laboratories).
VERACYTE, INC. (VCYT) has a market capitalization of $4.73 B as of 2026-07-09, ranking #1462 among US-listed companies.
VERACYTE, INC. reported revenue of $517.14M for fiscal year 2025, an increase of 16.0% year over year.
Yes. VERACYTE, INC. reported net income of $66.40M in its latest fiscal year.